Adagio Closes $42.5M Financing To Develop Ablation Technologies
The series E financing will support the ongoing US trial of Adagio’s iCLAS cardiac cryoablation system and development of Adagio's pulsed field cryoablation technology while the company continues to commercialize iCLAS outside the US.
You may also be interested in...
Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.